Form 4 for TMO Thermo Fisher Scientific

Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001127602-25-006223 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2025-02-21	2025-02-19	TMO	Williamson Stephen	SVP, CFO	A - Grant	$0.00	+7,942	28.8K	+38%	$0
D	2025-02-21	2025-02-19	TMO	Williamson Stephen	SVP, CFO	A - Grant	$0.00	+9,398	9,398	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-19	A	A	6,409	$0.00	35,237.81	D	—	—	(F1) Shares represent a performance-based restricted stock unit award granted on February 21, 2024. The Company's Compensation Committee determined on February 19, 2025, that the performance criteria related to this award were satisfied. One-third of the shares vest on February 28, 2025 and 2026. The remaining one-third will vest on February 28, 2027, and is subject to adjustment (positive or negative) for long-term performance which is based on the comparison of the Company's total shareholder return compound annual growth rate ("CAGR") to the total shareholder return CAGR of each of the companies in the peer group, as specified within the award agreement, over the measurement period starting on January 1, 2024, through to December 31, 2026.
2	Common	Common Stock	2025-02-19	A	A	1,533	$0.00	28,828.81	D	—	—
3	Derivative	Stock Option (Right to Buy)	2025-02-19	A	A	9,398	$0.00	9,398	D	$530.86 · — to 2035-02-19	9,398 Common Stock	(F3) The option vests in four equal annual installments beginning on February 28, 2026.